Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Geron

This page shows the latest Geron news and features for those working in and with pharma, biotech and healthcare.

Geron poleaxed as partner J&J abandons only pipeline drug

Geron poleaxed as partner J&J abandons only pipeline drug

Geron expects the transition of the complete imetelstat program to occur over approximately 12 months with operational support from Janssen,” said Scarlett. ... A lot will rest on data from the two trials that Geron hopes to present at the American

Latest news

  • J&J aiming for above-average growth thanks to stream of blockbusters J&J aiming for above-average growth thanks to stream of blockbusters

    Also name-checked in the R&D update was imetelstat for myelofibrosis, which J&J is co-developing with Geron for a number of indications under a $934m deal agreed in

  • First human embryonic stem cell trial

    Initiating the GRNOPC1 clinical trial is a milestone for the field of human embryonic stem cell-based therapies," said Geron president and CEO, Dr Thomas B Okarma. ... According to Geron, around 12, 000 people a year in the US receive spinal cord injuries

  • FDA lifts hold on stem-cell trial

    The US Food and Drug Administration has lifted its hold on Geron's phase I study of GRNOPC1 – the first-ever human embryonic stem cell-based therapy. ... The federal agency lifted the hold based on Geron's completion of an additional confirmatory

  • Switched on

    In January 2009 the FDA granted permission for Geron Corp to initiate a Phase I multicentre trial for its embryonic stem cell based therapy for spinal cord injuries (GRNOPC1).

  • University of Washington wins stem cell research grant

    The team collaborates with the US-headquartered biotechnology firm, Geron, in this area.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    95. Geron / J&J. Licence. Exclusive worldwide rights to Geron's oligonucleotide backbone chemistry, as well as novel amidates for RNAi.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Licence. 1, 051. Geron Corporation / J&J (Janssen). GRN163L, Imetelstat and tolerase inhibitor.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • V Bryan Lawlis joins board of KaloBios V Bryan Lawlis joins board of KaloBios

    Dr Lawlis is current president and CEO of Itero Biopharmaceuticals and is a director at several other life sciences companies including Biomarin Pharmaceutical, Geron, and Sutro Biopharmaceuticals.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Time to talk about health inequalities
Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...

Quick links